The CYP2C19*2 Genotype Predicts Tamoxifen Treatment Outcome in Advanced Breast Cancer Patients

10.1038/nrd1031

10.1002/cncr.23192

10.1200/JCO.1995.13.2.513

10.2165/00003088-199222050-00002

10.1093/jnci/djg108

Dehal SS , KupferD. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res.57(16) , 3402–3406 (1997).

10.1016/S0006-2952(96)00650-8

10.1016/S0021-9258(19)70058-1

Coezy E , BorgnaJL, RochefortH. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res.42(1) , 317–323 (1982).

10.1007/BF01806449

10.1023/B:BREA.0000025406.31193.e8

10.1093/jnci/dji005

10.1158/0008-5472.CAN-08-3933

10.1007/s10549-006-9428-0

10.1200/JCO.2005.03.3266

10.1001/jama.2009.1420

10.1373/clinchem.2008.121756

10.1158/1078-0432.CCR-08-2006

10.2217/pgs.10.112

10.1002/path.2455

10.1007/s10549-008-9939-y

10.1200/JCO.2004.01.072

10.1093/jnci/dji237

10.1124/jpet.104.065607

10.1093/carcin/15.12.2733

10.1016/j.bcp.2006.01.004

10.1200/JCO.1992.10.2.304

10.1093/jnci/83.20.1477

10.1016/S0140-6736(05)80088-1

10.1200/JCO.2007.12.2705

10.1007/s10549-008-0076-4

Dunn BK , GreeneMH, KelleyJM et al. Novel pathway analysis of genomic polymorphism-cancer risk interaction in the breast cancer prevention trial. Int. J. Mol. Epidemiol. Genet. 1(4) , 332–349 (2010).

10.1124/dmd.30.8.869

10.1016/S0006-2952(02)00994-2

10.1186/bcr1539

10.1046/j.1365-2125.2002.01614.x

Summary of the ATAC and BI1–98 trial outcomes on the role of CYP2D6 in tamoxifen therapy as presented at the San Antonio Breast Cancer Conference TX USA 8–13 December (2010) www.medscape.com/viewarticle/734220

Dutch federation of Biomedical Scientific Societies Code of Conduct www.fmwv.nl